Vaccine effectiveness studies in the field

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889 · see citing works

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831 · see citing works

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Vasileiou, E., Simpson, C. R., Shi, T., Kerr, S., Agrawal, U., Akbari, A., Bedston, S., Beggs, J., Bradley, D., Chuter, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00677-2 · Cited by 549 · see citing works

Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study

Hitchings, M. D. T., Ranzani, O., Torres, M. S. S., de Oliveira, S. B., Almirón, M., Said, R., Borg, R., Schulz, W. L., de Oliveira, R. D., da Silva, P. V., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100025 · Cited by 200 · see citing works

The Use of Test-negative Controls to Monitor Vaccine Effectiveness

Chua, H., Feng, S., Lewnard, J. A., Sullivan, S. G., Blyth, C. C., Lipsitch, M., & Cowling, B. J. (2019) · Epidemiology · doi:10.1097/ede.0000000000001116 · Cited by 165 · see citing works

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Linsenmeyer, K. D., Gupta, K., & Charness, M. E. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2113090 · Cited by 157 · see citing works

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC

Wall, E. C., Wu, M., Harvey, R., Kelly, G. P., Warchal, S., Sawyer, C., Daniels, R. S., Adams, L., Hobson, P. S., Hatipoglu, E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01462-8 · Cited by 116 · see citing works

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants

Choi, A., Koch, M., Wu, K., Dixon, G., Oestreicher, J., Legault, H. M., Stewart-Jones, G. B. E., Colpitts, T., Pajón, R., Bennett, H., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01313-21 · Cited by 113 · see citing works

Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines

Lewnard, J. A., Patel, M. M., Jewell, N. P., Verani, J. R., Kobayashi, M., Tenforde, M. W., Dean, N. E., Cowling, B. J., & Lopman, B. A. (2021) · Epidemiology · doi:10.1097/ede.0000000000001366 · Cited by 103 · see citing works

Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada

Skowronski, D. M., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J. R., Galanis, E., Naus, M., Patrick, D. M., Sbihi, H., Adam, S. E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab616 · Cited by 45 · see citing works

Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concernPreprint

Jongeneelen, M. A. C., Kaszás, K., Veldman, D., Huizingh, J., van der Vlugt, R., Schouten, T. G., Zuijdgeest, D., Uil, T. G., Roey, G. V., Guimerà, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.01.450707 · Cited by 44 · see citing works

COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United StatesPreprint

Moghadas, S. M., Sah, P., Fitzpatrick, M. C., Shoukat, A., Pandey, A., VILCHES, T. N., Singer, B. H., Schneider, E. C., & Galvani, A. P. (2021) · medRxiv · doi:10.1101/2021.07.07.21260156 · Cited by 36 · see citing works

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants

(2021) · doi:10.1101/2021.06.28.449914 · Cited by 28 · see citing works

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590 · see citing works

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., et al. (2021) · doi:10.1101/2021.08.18.21262237 · Cited by 543 · see citing works

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

Arbel, R., Hammerman, A., Sergienko, R., Friger, M., Peretz, A., Netzer, D., & Yaron, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2115624 · Cited by 339 · see citing works

Covid-19 Vaccine Effectiveness and the Test-Negative Design

Dean, N. E., Hogan, J. W., & Schnitzer, M. E. (2021) · New England Journal of Medicine · doi:10.1056/nejme2113151 · Cited by 168 · see citing works

The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern

Akkız, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.849217 · Cited by 100 · see citing works

Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform

Nab, L., Parker, E. P. K., Andrews, C. D., Hulme, W. J., Fisher, L., Morley, J., Mehrkar, A., MacKenna, B., Inglesby, P., Morton, C. E., et al. (2023) · The Lancet Public Health · doi:10.1016/s2468-2667(23)00079-8 · Cited by 97 · see citing works

Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers

Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103805 · Cited by 73 · see citing works

Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study

Wright, B. J., Tideman, S., Diaz, G. A., French, T., Parsons, G., & Robicsek, A. A. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00042-x · Cited by 68 · see citing works

Facilitators and barriers to COVID-19 vaccine uptake among women in two regions of Ghana: A qualitative study

Afrifa-Anane, G. F., Larbi, R. T., Addo, B., Agyekum, M. W., Kyei‐Arthur, F., Appiah, M., Agyemang, C. O., & Sakada, I. G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272876 · Cited by 44 · see citing works

Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target?

Srinivasan, K., Pandey, A. K., Livingston, A., & Venkatesh, S. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00060-1 · Cited by 33 · see citing works

Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage

Lewnard, J. A., Mahale, P. S., Malden, D. E., Hong, V. X., Ackerson, B. K., Lewin, B. J., Link‐Gelles, R., Feldstein, L. R., Lipsitch, M., & Tartof, S. Y. (2024) · Nature Communications · doi:10.1038/s41467-024-52668-w · Cited by 28 · see citing works

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection

Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-García, J., O’Horo, J. C., Virk, A., Swift, M. D., Gordon, J. E., Speicher, L. L., et al. (2021) · Med · doi:10.1016/j.medj.2021.12.002 · Cited by 30 · see citing works

Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study

Барчук, А. А., Cherkashin, M., Bulina, A., Berezina, N., Rakova, T., Kuplevatskaya, D., Stanevich, O. V., Skougarevskiy, D., & Okhotin, A. (2022) · BMC Medicine · doi:10.1186/s12916-022-02509-8 · Cited by 29 · see citing works

Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More

Lippi, G., & Favaloro, E. J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1736168 · Cited by 27 · see citing works

SARS-CoV-2 ORF3c impairs mitochondrial respiratory metabolism, oxidative stress, and autophagic flux

Mozzi, A., Oldani, M., Forcella, M. E., Vantaggiato, C., Cappelletti, G., Pontremoli, C., Valenti, F., Forni, D., Saresella, M., Biasin, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107118 · Cited by 28 · see citing works

The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA

Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 21 · see citing works

Omicron mutations increase interdomain interactions and reduce epitope exposure in the SARS-CoV-2 spike

Wieczór, M., Tang, P. K., Orozco, M., & Cossio, P. (2023) · iScience · doi:10.1016/j.isci.2023.105981 · Cited by 20 · see citing works

Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?

Lippi, G., Henry, B. M., & Plebani, M. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0972 · Cited by 17 · see citing works

COVID‐19 cooling: Nanostrategies targeting cytokine storm for controlling severe and critical symptoms

Zheng, Y., Li, Y., Mao, L., Wang, R., Jiang, Y., Zhao, M., Lu, J. L., Li, R., Li, X., & Shi, S. (2023) · Medicinal Research Reviews · doi:10.1002/med.21997 · Cited by 17 · see citing works

Association of disease severity and death outcome with vaccination status of admitted COVID-19 patients in delta period of SARS-COV-2 in mixed variety of vaccine background

Aslam, J., Hassan, M. R. U., Fatima, Q., Hashmi, H. B., Alshahrani, M. Y., Alkhathami, A. G., & Aneela, I. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.103329 · Cited by 17 · see citing works

Data-Driven Prediction for COVID-19 Severity in Hospitalized Patients

Alrajhi, A. A., Alswailem, O., Wali, G. Y., Alnafee, K., AlGhamdi, S., Alarifi, J., AlMuhaideb, S., ElMoaqet, H., & AbuSalah, A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19052958 · Cited by 16 · see citing works

Mathematical modeling for Delta and Omicron variant of SARS-CoV-2 transmission dynamics in Greece

Liossi, S., Tsiambas, E., Maipas, S., Papageorgiou, E., Lazaris, A. C., & Kavantzas, N. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.07.002 · Cited by 13 · see citing works

Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies

Chang, S., Liu, H., Wu, J., Xiao, W., Chen, S., Qiu, S., Duan, G., Song, H., & Zhang, R. (2022) · Vaccines · doi:10.3390/vaccines10030469 · Cited by 12 · see citing works

Increased vaccine sensitivity of an emerging SARS-CoV-2 variant

Lewnard, J. A., Hong, V. X., Kim, J. S., Shaw, S. F., Lewin, B. J., Takhar, H. S., Lipsitch, M., & Tartof, S. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-39567-2 · Cited by 11 · see citing works

Covid-19: Two vaccine doses are crucial for protection against delta, study finds

Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n2029 · Cited by 12 · see citing works

Estimating Conditional Vaccine Effectiveness

Ioannidis, J. P. A. (2022) · European Journal of Epidemiology · doi:10.1007/s10654-022-00911-3 · Cited by 11 · see citing works

SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic review

Rustagi, V., Gupta, S. R. R., Talwar, C., Singh, A., Xiao, Z.-Z., Jamwal, R., Bala, K., Bhaskar, A. K., Nagar, S., & Singh, I. K. (2024) · Immunologic Research · doi:10.1007/s12026-024-09553-x · Cited by 12 · see citing works

Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study

Monteiro, H. S., Neto, A. S. L., Kahn, R. J., de Sousa, G. D. S., Carmona, H. A., Andrade, J. S., & Castro, M. C. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.065 · Cited by 9 · see citing works

The impact of underreported infections on vaccine effectiveness estimates derived from retrospective cohort studies

Sacco, C., Manica, M., Marziano, V., Fabiani, M., Mateo‐Urdiales, A., Guzzetta, G., Merler, S., & Pezzotti, P. (2024) · International Journal of Epidemiology · doi:10.1093/ije/dyae077 · Cited by 8 · see citing works

The impact of health status on attitudes toward COVID‐19 vaccination

Moustafa, A., Safi, M. F., Opoku, M. P., & Mohamed, A. M. (2022) · Health Science Reports · doi:10.1002/hsr2.744 · Cited by 9 · see citing works

Evaluating COVID-19 infection prevention measures in Malaysia: A fuzzy DEMATEL approach

Yadegaridehkordi, E., Nilashi, M., Nasir, M. H. N. M., Satar, N. S. M., & Momtazi, S. (2023) · Digital Health · doi:10.1177/20552076231211670 · Cited by 8 · see citing works

Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023

Lee, J. A., Jang, H., Ahn, S. M., Seong, J. E., Kim, Y. K., Sohn, Y., Jung, S., Jeong, H. W., Kim, S., Lee, J. S., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107249 · Cited by 8 · see citing works

Estimating Vaccine Effectiveness by Linking Population-Based Health Registries: Some Sources of Bias

Brookmeyer, R., & Morrison, D. E. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac145 · Cited by 7 · see citing works

Infection Risk Prediction Model for COVID-19 Based on an Analysis of the Settlement of Particles Generated during Dental Procedures in Dental Clinics

Baldión, P. A., Oliveros, H., Guerrero, C. A., González, A. C. C., & Betancourt, D. E. (2021) · International Journal of Dentistry · doi:10.1155/2021/7832672 · Cited by 6 · see citing works

Socioeconomic and risk-related drivers of compliance with measures to prevent SARS-CoV-2 infection: evidence from the Munich-based KoCo19 study

Pedron, S., Laxy, M., Radon, K., Gleut, R. L., Castelletti, N., Noller, J. M. G., Diefenbach, M. N., Hölscher, M., Leidl, R., Schwettmann, L., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-15759-9 · Cited by 6 · see citing works

SARS-CoV-2 testing strategies for outbreak mitigation in vaccinated populations

Kumar, C. K., Balasubramanian, R., Ongarello, S., Carmona, S., & Laxminarayan, R. (2022) · medRxiv · doi:10.1371/journal.pone.0271103 · Cited by 5 · see citing works

Safety and Immunogenicity of Intranasal Razi Cov Pars as a COVID-19 Booster Vaccine in Adults: Promising Results from a Groundbreaking Clinical Trial

Mehrabadi, M. H. F., Hajimoradi, M., Es‐haghi, A., Kalantari, S., Noofeli, M., Mokarram, A. R., Razzaz, S. H., Taghdiri, M., Mokhberalsafa, L., Sadeghi, F., et al. (2024) · Vaccines · doi:10.3390/vaccines12111255 · Cited by 5 · see citing works

Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland

Anderegg, N., Althaus, C. L., Colin, S., Hauser, A., Laube, A., Mäusezahl, M., Wagner, M., Zaffora, B., & Riou, J. (2022) · Swiss Medical Weekly · doi:10.4414/smw.2022.w30163 · Cited by 5 · see citing works

Changes in Social and Clinical Determinants of COVID-19 Outcomes Achieved by the Vaccination Program: A Nationwide Cohort Study

Ibarrondo, O., Aguiar, M., Stollenwerk, N., Blasco-Aguado, R., Larrañaga, I., Bidaurrazaga, J., Estadilla, C. D. S., & Mar, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912746 · Cited by 5 · see citing works

The response of the scientific community to a global crisis: a systematic review of COVID-19 research in 2020

Srivastava, P. R., Zhang, Z., Eachempati, P., Trivedi, S. K., & Jasimuddin, S. M. (2022) · British Journal of Healthcare Management · doi:10.12968/bjhc.2021.0068 · Cited by 4 · see citing works

Coronavirus vaccination rates in cultural areas in Germany

Spahn, C., Hipp, A. M., Richter, B., & Nusseck, M. (2022) · Epidemiology and Infection · doi:10.1017/s0950268822000085 · Cited by 5 · see citing works

Six-month decline of serum anti-spike S1 subunit IgA in SARS-CoV-2 in seronegative healthcare workers after mRNA-based COVID-19 vaccinationPreprint

Salvagno, G. L., Henry, B. M., Pighi, L., NITTO, S. D., & Lippi, G. (2021) · Research Square · doi:10.21203/rs.3.rs-1019658/v1 · Cited by 4 · see citing works

Should More Patients with Kidney Failure Bring Treatment Home? What We Have Learned from COVID-19

Yu, X., Jha, V., & Nakamoto, H. (2022) · Kidney Diseases · doi:10.1159/000525046 · Cited by 3 · see citing works

International cooperation during COVID‐19: Case study vaccine cooperation and its impact in Indonesia

Pratiwi, F. I., Muttaqien, M., Samy, M., Fadli, J. H., Intan, A. A., & Kusuma, N. R. (2022) · Asian Politics & Policy · doi:10.1111/aspp.12643 · Cited by 3 · see citing works

A brief history of the COVID-19 pandemic: perspectives in risk science and data analytics

Trump, B. D., Keenan, J. M., & Linkov, I. (2025) · Journal of Risk Research · doi:10.1080/13669877.2025.2569437 · Cited by 2 · see citing works

Nasal Mucosa Exploited by SARS-CoV-2 for Replicating and Shedding during Reinfection

Li, H., Zhao, X., Li, J., Zheng, H.-W., Zhao, Y.-R., Yang, J.-L., Zhou, J.-X., Yang, F., Chen, Y.-L., Zuo, Y., et al. (2022) · Viruses · doi:10.3390/v14081608 · Cited by 2 · see citing works

Contested bodies and delayed decisions: Attitudes to COVID-19 vaccines among Jamaicans

Smith, A. Y. (2022) · OPERA · doi:10.18601/16578651.n32.10 · Cited by 2 · see citing works

Pandemic escape plan: Discontinuing policies that have reached their expiry date

van Zyl, G. U., Dramowski, A., & Preiser, W. (2022) · South African Medical Journal · doi:10.7196/samj.2022.v112i3.16381 · Cited by 1 · see citing works

Investing to kill: return on investment of tobacco companies compared to high-mortality and neutral industries

Hollman, M. R., & Pearce, J. M. (2022) · Global Security Health Science and Policy · doi:10.1080/23779497.2022.2038035 · Cited by 2 · see citing works

Editorial: Oral antivirals for mild-moderate COVID-19: a panacea or a logistical and clinical conundrum?

Coombes, I., Legg, A., Patterson, T., Kelly, T., Henderson, A., & Roberts, J. A. (2022) · Australian Prescriber · doi:10.18773/austprescr.2022.021 · Cited by 2 · see citing works

SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study

Domènech-Montoliu, S., Pérez-Olaso, Ó., Sala-Trull, D., Rio-Gonzalez, A. D., López-Diago, L., Aleixandre-Gorriz, I., Pac-Sa, M. R., Sanchéz-Urbano, M., Sarorres-Martinez, P., Notari-Rodriguez, C., et al. (2025) · Epidemiologia · doi:10.3390/epidemiologia7010001 · Cited by 1 · see citing works

COVID-19 breakthrough infection among vaccinated individuals: A cross-sectional study

Chavan, S., Suryawanshi, M., Pagar, V., Patil, S., & Kinge, A. D. (2022) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v13i7.44473 · Cited by 1 · see citing works

Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study

Arrospide, A., Sagardui, M. G., Larizgoitia, I., Iturralde, A., Moreda, A. B., & Mar, J. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.061 · Cited by 1 · see citing works

A commentary on “PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron”

Muthu, S., & Venkatesh, S. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.87 · Cited by 1 · see citing works

Systematic review of cardiac adverse effects in children and young people under 18 years of age after SARS-CoV-2 vaccinationPreprint

Cruz, J., Duret, A., Harwood, R., Fraser, L., Jones, C. B., Ward, J., Whittaker, E., Kenny, S. E., & Viner, R. (2021) · medRxiv · doi:10.1101/2021.12.06.21267339 · Cited by 1 · see citing works

SARS-CoV-2 ORF3c impairs mitochondrial respiratory metabolism, oxidative stress and autophagic flowPreprint

Mozzi, A., Oldani, M., Forcella, M. E., Vantaggiato, C., Cappelletti, G., Pontremoli, C., Valenti, F., Forni, D., Biasin, M., Sironi, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.04.510754 · Cited by 1 · see citing works

Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection from routine surveillance data in SwitzerlandPreprint

Anderegg, N., Althaus, C. L., Colin, S., Hauser, A., Laube, A., Mäusezahl, M., Wagner, M. G., Zaffora, B., & Riou, J. (2021) · doi:10.31219/osf.io/rxk9b

Distinct Vaccine Efficacy Rates Among Health Care Workers During a COVID-19 Outbreak in JordanPreprint

Sultan, I. Y., Tbakhi, A., Abuatta, O., Mubarak, S., Alsmadi, O. A., Edilbi, A., Al-Ani, R., Makhlouf, M., Hajir, R., Khreisat, O., et al. (2022) · medRxiv · doi:10.1101/2022.01.15.22269356

Risk Factors for Admission Within a Hospital-Based COVID-19 Home Monitoring Program

Sperring, H., Hofman, M., Hsu, H., Xiao, Y., Keohane, E. A., Lodi, S., Marathe, J. G., & Epstein, R. L. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac320

Das Immunsystem

(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-45305-2.00007-4

Infección por SARS-CoV-2 posterior a la inmunización artificial e híbrida en el personal de salud

López-Contreras, J. E., Castillo-Vélez, F. E., Gutierrez, G. M., Marrón, J. S., Martínez, E. P. S., & Paredes-Casillas, P. (2022) · ALERTA Revista Científica del Instituto Nacional de Salud · doi:10.5377/alerta.v5i2.14395

Signal detection of COVID ‐19 vaccines adverse events using spontaneous reports from South Korea

Jeong, H. S., & Chun, B. C. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5629

Vaccine Effectiveness against GP-Attended Symptomatic COVID-19 and Hybrid Immunity among Adults in Hungary during the 2022–2023 Respiratory Season Dominated by Different SARS-CoV-2 Omicron Subvariants

Horváth, J. K., Túri, G., Krisztalovics, K., Kristóf, K., & Oroszi, B. (2024) · Vaccines · doi:10.3390/vaccines12050496

Test-Negative Designs with Multiple Testing SourcesPreprint

Yu, M., & Jewell, N. P. (2025) · medRxiv · doi:10.1101/2025.04.26.25326477

Additional file 1 of Socioeconomic and risk-related drivers of compliance with measures to prevent SARS-CoV-2 infection: evidence from the Munich-based KoCo19 study

Pedron, S., Laxy, M., Radon, K., Gleut, R. L., Castelletti, N., Noller, J. M. G., Diefenbach, M. N., Hölscher, M., Leidl, R., & Schwettmann, L. (2024) · Figshare · doi:10.6084/m9.figshare.26588736

Effectiveness of an Inactivated SARS-CoV-2 Vaccine

Chi, H., Chiu, N.-C., & Lin, C.-Y. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2112423 · Cited by 14 · see citing works

Covid-19 Vaccine Effectiveness and the Test-Negative Design

Dean, N. E., Hogan, J. W., & Schnitzer, M. E. (2021) · New England Journal of Medicine · doi:10.1056/nejme2113151 · Cited by 168 · see citing works

Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel

Swift, M. D., Breeher, L. E., Tande, A. J., Tommaso, C. P., Hainy, C. M., Chu, H., Murad, M. H., Berbari, E. F., & Virk, A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab361 · Cited by 98 · see citing works

Additional file 1 of Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis

Liu, Q., Qin, C., Liu, M., & Liu, J. (2021) · Figshare · doi:10.6084/m9.figshare.17010246

Vaccination Against SARS-CoV-2: Efficacy and Side Effects

Harfouch, R. (2022) · International Journal of Clinical Studies and Medical Case Reports · doi:10.46998/ijcmcr.2022.20.000476 · Cited by 1 · see citing works